Amylyx selects AMX0318 as development candidate for PBH

Amylyx (AMLX) announced the selection of AMX0318, a long-acting glucagon-like peptide-1 receptor antagonist, as a development candidate for post-bariatric hypoglycemia, or PBH, and other rare diseases. AMX0318 was identified through a research collaboration with Gubra, a company specializing in peptide-based drug discovery and preclinical contract research services. Amylyx expects the program to advance into investigational new drug-enabling studies later this year, with an IND targeted for 2027, pending successful completion of IND-enabling studies. Under the terms of the research collaboration, Gubra is eligible to receive more than $50M in success-based development and commercialization milestones plus mid-single digit royalties on worldwide net sales. The selection and handover of the development candidate will provide milestone payments of $4M to Gubra.